Salmonella gastroenteritis in children: six-year experience in İstanbul, Turkey.


Journal

Journal of infection in developing countries
ISSN: 1972-2680
Titre abrégé: J Infect Dev Ctries
Pays: Italy
ID NLM: 101305410

Informations de publication

Date de publication:
29 11 2022
Historique:
received: 29 06 2022
accepted: 15 09 2022
entrez: 30 11 2022
pubmed: 1 12 2022
medline: 3 12 2022
Statut: epublish

Résumé

The aim of this study was to evaluate the demographic and clinical characteristics and treatment outcomes of children with Salmonella gastroenteritis. We retrospectively reviewed the medical records of pediatric patients aged between 1 month and 18 years with the diagnosis of Salmonella gastroenteritis between May 2015 and December 2021. A total of 172 children diagnosed with Salmonella gastroenteritis, including 113 outpatients and 59 hospitalized children, were included in this study. There were 95 (55.2%) males and 77 (44.8%) females with a median age of 59.5 months (interquartile range [IQR]: 33.5-96 months, min-max: 1-205 months). The most common clinical symptoms were diarrhea (n = 166, 96.5%), fever (n = 113, 65.7%) and abdominal pain (n = 73, 42.4%). Bloody diarrhea was seen in 19.2% of patients. Fifty (29.1%) of the Salmonella species could not be typed. Serogroup D (n = 106, 61.6%) was the predominant serogroup isolated from stool cultures, followed by serogroup B (n = 16, 9.3%). 62.2% of the isolates were susceptible to ampicillin, 97.7% to ciprofloxacin, 98.8% to trimethoprim-sulfamethoxazole, and 98.8% to ceftriaxone. Fever, vomiting, and underlying disease occurred more frequently in hospitalized patients than in outpatients (p: 0.005, p: 0.000, p: 0.000, respectively). C-reactive protein value was found to be higher in hospitalized patients (p: 0.000). Salmonella should be considered as a causative agent in pediatric patients with abdominal pain, fever, and bloody-mucous diarrhea, and patients with severe clinical conditions should be hospitalized and antibiotic therapy initiated if indicated.

Identifiants

pubmed: 36449648
doi: 10.3855/jidc.17042
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1757-1761

Informations de copyright

Copyright (c) 2022 Ayse Karaaslan, Ceren Cetin, Mehmet Tolga Kole, Serap Demir Tekol, Elif Sobu, Yasemin Akin.

Déclaration de conflit d'intérêts

No Conflict of Interest is declared

Auteurs

Ayşe Karaaslan (A)

Department of Pediatric Infectious Diseases, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey. akaraaslan78@gmail.com.

Ceren Çetin (C)

Department of Pediatric Infectious Diseases, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey.

Mehmet Tolga Köle (MT)

Department of Pediatrics, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey.

Serap Demir Tekol (S)

Department of Microbiology, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey.

Elif Söbü (E)

Department of Pediatrics, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey.

Yasemin Akın (Y)

Department of Pediatrics, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH